Cystic Fibrosis (CF) is the most common fatal genetic disorder in white-race communities with a prevalence of 1:2500. Mutation in CFTR gene is its main cause (
1-
4), yet the reason of this genetic anomaly is unknown (
3). Clinical progression of CF is highly variable. While malabsorption is the initial sign, other frequent manifestations are fatty diarrhea, recurrent respiratory infections, and failure to thrive (FTT) (
5,
6). The main reason of mortality and morbidity in CF patients is pulmonary involvement (
7-
9). In various studies, it has been shown that quantitative evaluation of parenchymal changes in lung HRCT of CF patients measured by the 2006-revised Brody scoring is compatible with the clinical status (
1-
6). Patients with CF are mostly children, unable to perform complicated pulmonary tests. On the other hand, screening tests are not performed in many countries, such as Iran, resulting in late diagnosis in older ages with more diffuse parenchymal involvement and longer hospitalization. Consequently, the quantitative measurement of parenchymal changes in lung high-resolution computed tomography (HRCT) seems to be useful for early and accurate evaluation of the patients’ clinical status.